Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Fainting Detection And Early Warning In Syncope Evaluation Study (ARISE)

NCT: NCT07502599 · NOT_YET_RECRUITING

NCT IDNCT07502599
StatusNOT_YET_RECRUITING
Start Date2026-06
Completion2028-08

Brief Summary

To characterize the impact of orthostatic hypotension (OH) and Vasovagal syncope on signals measured using a wearable Holter monitor in the clinic and ambulatory setting. To evaluate the relationship of signals measured from the Holter monitor with reported symptom severity of orthostatic intolerance per standard data collection, analysis, and questionnaires.

Frequently Asked Questions

What is Fainting Detection And Early Warning In Syncope Evaluation Study (ARISE)?

Fainting Detection And Early Warning In Syncope Evaluation Study (ARISE) is a clinical trial registered under NCT07502599. Current status: NOT_YET_RECRUITING.

What is the status of NCT07502599?

The current status of NCT07502599 (Fainting Detection And Early Warning In Syncope Evaluation Study (ARISE)) is: NOT_YET_RECRUITING.

When did Fainting Detection And Early Warning In Syncope Evaluation Study (ARISE) start?

Fainting Detection And Early Warning In Syncope Evaluation Study (ARISE) started on 2026-06.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑